- Current report filing (8-K)
July 08 2011 - 9:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): July 7, 2011
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-19700
|
|
33-0266089
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and
zip code)
Registrants telephone number, including area code: (858) 552-2200
Check the appropriate box below if the Form 8K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CRF 240.13e4(c))
|
On
July 7, 2011, Amylin Pharmaceuticals, Inc. (Amylin) issued a press release announcing results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma
concentrations. The study was conducted to satisfy a requirement by the U.S. Food and Drug Administration in support of the New Drug Application for BYDUREON (exenatide extended-release for injectable suspension), an investigational medication
for type 2 diabetes. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
|
|
|
Number
|
|
Description
|
|
|
99.1
|
|
Press release issued by Amylin on July 7, 2011.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
AMYLIN PHARMACEUTICALS, INC.
|
|
|
|
Dated: July 8, 2011
|
|
By:
|
|
/s/ HARRY J. LEONHARDT
|
|
|
|
|
Harry J. Leonhardt
|
|
|
|
|
Vice President, Legal and Governance, and Corporate Secretary
|
EXHIBIT INDEX
|
|
|
Number
|
|
Description
|
|
|
99.1
|
|
Press release issued by Amylin on July 7, 2011.
|
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From May 2024 to Jun 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2023 to Jun 2024